Mutations in p53, p53 protein overexpression and breast cancer survival

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 3847-3857

  Rossner Jr, Pavel ^a,b   Gammon, Marilie D ^c   Zhang, Yu Jing ^a   Terry, Mary Beth ^a   Hibshoosh, Hanina ^d   Memeo, Lorenzo ^e   Mansukhani, Mahesh ^d   Long, Chang Min ^a   Garbowski, Gail ^a   Agrawal, Meenakshi ^a   Kalra, Tara S ^a   Gaudet, Mia M ^c   Teitelbaum, Susan L ^f   Neugut, Alfred I ^a   Santella, Regina M ^a  

^a Columbia University ^*  (United States)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^c IL   (United States)

^d Pathology Unit Mediterranean Institute of Oncology ^*  (United States)

^e Pathology Unit Mediterranean Institute of Oncology   (Italy)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; P53 mutations; P53 overexpression; Survival

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CASE CONTROL STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; MIDDLE AGED; MORTALITY; MUTATION; RISK; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; ODDS RATIO; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77649155782     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00553.x     Document Type: Article

References (56)

1. Braithwaite AW, Royds JA, Jackson P. The p53 story: layers of complexity. Carcinogenesis. 2005, 26:1161-9.
2. Olivier M, Hainaut P. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin Cancer Biol. 2001, 11:353-60.
3. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat. 2003, 21:292-300.
4. Hill KA, Sommer SS. p53 as a mutagen test in breast cancer. Environ Mol Mutagen. 2002, 39:216-27.
5. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006, 13:293-325.
6. Hall PA, McCluggage WG. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J Pathol. 2006, 208:1-6.
7. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat. 1998, 52:79-98.
8. Pakos EE, Kyzas PA, Ioannidis JP. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clin Cancer Res. 2004, 10:6208-14.
9. Malats N, Bustos A, Nascimento CM. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005, 6:678-86.
10. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer. 1999, 80:1968-73.
11. Olivier M, Langerod A, Carrieri P. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006, 12:1157-67.
12. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004, 9:606-16.
13. Gammon MD, Neugut AI, Santella RM. The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat. 2002, 74:235-54.
14. Cleveland RJ, Eng SM, Abrahamson PE. Weight gain prior to breast cancer diagnosis and survival. Cancer Epidemiol Biomarkers Prev. 2007, 16:1803-11.
15. Fink BN, Gaudet MM, Britton JA. Fruits, vegetables, and micronutrient intake in relation to breast cancer survival. Breast Cancer Res Treat. 2006, 98:199-208.
16. Gaudet MM, Britton JA, Kabat GC. Fruits, vegetables, and micronutrients in relation to breast cancer modified by menopause and hormone receptor status. Cancer Epidemiol Biomarkers Prev. 2004, 13:1485-94.
17. Qiu P, Shandilya H, D'Alessio JM. Mutation detection using Surveyor nuclease. Biotechniques. 2004, 36:702-7.
18. Hosmer DW, Lemeshow S. Applied logistic regression. 1989, New York, John Wiley & Sons
19. Hosmer DW, Lemeshow S. Applied survival analysis: regression modeling of time to event data. 1999, New York, John Wiley & Sons, Inc.
20. Olivier M, Eeles R, Hollstein M. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002, 19:607-14.
21. Bannwarth S, Procaccio V, Paquis-Flucklinger V. Surveyor nuclease: a new strategy for a rapid identification of heteroplasmic mitochondrial DNA mutations in patients with respiratory chain defects. Hum Mutat. 2005, 25:575-82.
22. Nowak D, Mossner M, Baldus CD. Mutation analysis of hCDC4 in AML cells identifies a new intronic polymorphism. Int J Med Sci. 2006, 3:148-51.
23. Mitani N, Niwa Y, Okamoto Y. Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy. Ann Clin Biochem. 2007, 44:557-9.
24. Lukas J, Niu N, Press MF. p53 mutations and expression in breast carcinoma in situ. Am J Pathol. 2000, 156:183-91.
25. Iwase H, Ando Y, Ichihara S. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast. Breast Cancer. 2001, 8:98-104.
26. Thorlacius S, Thorgilsson B, Bjornsson J. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer. 1995, 31A:1856-61.
27. Naidu R, Yadav M, Nair S. Immunohistochemical analysis of p53 expression in primary breast carcinomas. Anticancer Res. 1998, 18:65-70.
28. Tan PH, Chuah KL, Chiang G. Correlation of p53 and cerbB2 expression and hormonal receptor status with clinicopathologic parameters in ductal carcinoma in situ of the breast. Oncol Rep. 2002, 9:1081-6.
29. Erdem O, Dursun A, Coskun U. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. Tumori. 2005, 91:46-52.
30. McCabe A, Dolled-Filhart M, Camp RL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst. 2005, 97:1808-15.
31. Schmitt FC, Soares R, Cirnes L. P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach. Pathol Res Pract. 1998, 194:815-9.
32. Umekita Y, Kobayashi K, Saheki T. Nuclear accumulation of p53 protein correlates with mutations in the p53 gene on archival paraffin-embedded tissues of human breast cancer. Jpn J Cancer Res. 1994, 85:825-30.
33. Lisboa BW, Vogtlander S, Gilster T. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer. Virchows Arch. 1997, 431:375-81.
34. Lohmann D, Ruhri C, Schmitt M. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives. Diagn Mol Pathol. 1993, 2:36-41.
35. Nicolini A, Carpi A, Tarro G. Biomolecular markers of breast cancer. Front Biosci. 2006, 11:1818-43.
36. Putti TC, El-Rehim DM, Rakha EA. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2005, 18:26-35.
37. Gammon MD, Hibshoosh H, Terry MB. Cigarette smoking and other risk factors in relation to p53 expression in breast cancer among young women. Cancer Epidemiology Biomarkers Prev. 1999, 8:255-63.
38. Reed W, Hannisdal E, Boehler PJ. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer. 2000, 88:804-13.
39. Warnberg F, Nordgren H, Bergkvist L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer. 2001, 85:869-74.
40. Conway K, Edmiston SN, Cui L. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res. 2002, 62:1987-95.
41. Chappuis PO, Estreicher A, Dieterich B. Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay. Int J Cancer. 1999, 84:587-93.
42. Powell B, Soong R, Iacopetta B. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res. 2000, 6:443-51.
43. Overgaard J, Yilmaz M, Guldberg P. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol. 2000, 39:327-33.
44. Lai H, Ma F, Trapido E, Meng L. Spectrum of p53 tumor suppressor gene mutations and breast cancer survival. Breast Cancer Res Treat. 2004, 83:57-66.
45. Ho GH, Calvano JE, Bisogna M. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer. 2000, 89:2153-60.
46. Done SJ, Eskandarian S, Bull S. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2001, 93:700-4.
47. Kang JH, Kim SJ, Noh DY. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer. J Mol Med. 2001, 79:648-55.
48. Terry MB, Neugut AI, Schwartz S. Risk factors for a causal intermediate and an endpoint: reconciling differences. Am J Epidemiol. 2000, 151:339-45.
49. Thorlacius S, Borresen AL, Eyfjord JE. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res. 1993, 53:1637-41.
50. Boersma BJ, Howe TM, Goodman JE. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst. 2006, 98:911-9.
51. Barbareschi M. Prognostic value of the immunohistochemical expression of p53 in breast carcinomas-A review of the literature involving over 9,000 patients. Appl Immunohistochem. 1996, 4:106-16.
52. Dimitrakakis C, Konstadoulakis M, Messaris E. Molecular markers in breast cancer: can we use c-erbB-2, p53, bcl-2 and Bax gene expression as prognostic factors. Breast. 2002, 11:279-85.
53. Hlupic L, Jakic-Razumovic J, Bozikov J. Prognostic value of different factors in breast carcinoma. Tumori. 2004, 90:112-9.
54. Caffo O, Doglioni C, Veronese S. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res. 1996, 2:1591-99.
55. Montero S, Guzman C, Vargas C. Prognostic value of cytosolic p53 protein in breast cancer. Tumour Biol. 2001, 22:337-44.
56. Linjawi A, Kontogiannea M, Halwani F. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg. 2004, 198:83-90.